Sophie Hutchinson

A major Australian trial found that the MenB vaccine does not reduce gonorrhoea infections among men who have sex with men, contradicting earlier studies that suggested partial protection. UK health authorities will not change current vaccination guidance until further domestic data becomes available. Researchers and public health experts describe the results as disappointing but maintain that developing an effective gonorrhoea vaccine remains a priority amid rising infection rates and increasing antimicrobial resistance. Charity representatives urge policymakers to reassess the programme and stress the continued importance of condoms and regular STI testing.

A major Australian trial found that the MenB vaccine provides no protection against gonorrhoea among men who have sex with men, contradicting earlier studies that suggested a significant reduction in infections. UK health authorities will continue collecting data from more than 30,000 vaccinated individuals before considering any changes to the programme. Experts described the findings as disappointing but emphasised the ongoing need for a vaccine due to rising infection rates and increasing antibiotic resistance. Sexual health advocates called for a review of the current vaccination approach while stressing the continued importance of condoms and regular testing.